This trial is no longer recruiting

Recruitment for this study has ended, so applications are closed. You can still read the trial details, or browse similar trials that are currently recruiting.

Not recruiting
Phase 2

ChatBot & Activity Monitoring

Sponsor:

Abramson Cancer Center at Penn Medicine

Code:

NCT05318027

Conditions

Lung Cancer

Gastrointestinal Cancer

Head and Neck Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ChatBot

Study Details

Brief summary:

Evaluate the feasibility of using a chatbot combined with continuous activity monitoring to proactively identify, appropriately triage and help manage patients' symptoms during cancer treatment Determine whether such an early outpatient clinic-based intervention can decrease rates of excess triage visits

Correlate changes in activity and early symptom management to emergency department visits, unplanned inpatient hospitalizations and treatment breaks

Conditions

Lung Cancer

Gastrointestinal Cancer

Head and Neck Cancer

Study ID

NCT05318027

Start date

May 22, 2023

Status verified date

Jul, 2025

Completion date

Dec, 2025

Anticipated

Primary completion date

Dec, 2025

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Adults (age >18 years) with a diagnosis of a head and neck, lung, gastrointestinal cancer, that are receiving concurrent chemotherapy and radiation treatment.
  • Possession of a mobile device that can receive SMS texts and can deliver FitBit data wirelessly
  • Ability read and respond in English
  • Ability to provide informed consent to participate in the study

Exclusion Criteria:

  • Patients who are bed bound at baseline (ECOG 4)
  • Patients who rely on a wheelchair for ambulation

Study Design

Enrollment

70 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Other

Interventions and Outcome Measures

Arms

experimental: Activity Monitoring and ChatBot

Patients will receive standard of care chemotherapy and radiation therapy regimens, activity monitoring and utilize a ChatBot

no intervention: Activity Monitoring without ChatBot

Patients will receive standard of care chemotherapy and radiation therapy regimens, activity monitoring alone

Interventions

ChatBot

The automated chatbot will check in with the patient on two pre-specified days between scheduled outpatient visits. The chatbot will follow pre-specified symptom algorithms and classify symptoms as requiring high, intermediate and low risk follow ups. High risk symptoms will trigger a same day nursing/physician visit or telemedicine call/video. Intermediate risk symptoms will trigger a nursing triage visit or telemedicine call/video on the next day or treatment day. Low risk symptoms will notify the treating physician to address the symptoms at the next scheduled on treatment visit (OTV). If adjustments are needed in the chat bot triage algorithms, they will be updated in real time to decrease risk for adverse patient events.

Primary outcome measure

  • Number of triage visits [ Time Frame: 13 weeks ]

Central Contacts and Locations

Central contacts

Michell Kim

215-760-2487Michell.Kim@pennmedicine.upenn.edu

Locations

Abramson Cancer Center of the University of Pennsylvania

Recruiting

Philadelphia, Pennsylvania, United States, 19104

Contacts

Arun Goel, MD

215-662-6059Arun.Goel@pennmedicine.upenn.edu

More Information

Sponsor

Abramson Cancer Center at Penn Medicine

Last update posted

Aug 1, 2025

Last verified

Jul, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-12. This information was provided to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine on 2025-08-01.